Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Lead Sponsor:

Altor BioScience

Collaborating Sponsors:

Genentech, Inc.

Tanox

Conditions:

Sepsis

Acute Lung Injury

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven...

Detailed Description

Tissue factor (TF) is a transmembrane glycoprotein that acts as the principal initiator of the extrinsic coagulation pathway. TF is a key mediator between the immune system and coagulation and is the ...

Eligibility Criteria

Inclusion

  • ≥ 18 years
  • Suspected or proven bacterial infection
  • Receiving positive pressure ventilation through an endotracheal tube
  • Have ALI/ARDS, defined as having all of the following:
  • bilateral infiltrates consistent with pulmonary edema
  • Hypoxemia
  • no clinical evidence of left atrial hypertension
  • Provide signed informed consent

Exclusion

  • Mechanically or chemically-induced ALI/ARDS (including burns, trauma, and near drowning)
  • End-stage lung disease
  • Decompensated congestive heart failure
  • Authorization to withdraw life support
  • Hemoglobin persistently \<8.0 g/dL
  • Subjects who have any one of the following:
  • platelet count \<50,000/mm\^3
  • prolonged prothrombin time (PT)
  • prolonged activated partial thromboplastin time (aPTT)
  • having significant potential for disseminated intravascular coagulation (DIC)
  • Subjects who have two or more of the following:
  • prolonged aPTT
  • fibrinogen level below the lower limit of normal
  • presence of petechiae, ecchymoses, or other evidence of coagulopathy
  • Subjects who have a history of one or more of the following:
  • hematuria (microscopic or gross)
  • urinary tract neoplasia
  • nephrolithiasis
  • glomerulonephritis
  • active urinary tract infection (UTI)
  • Bleeding disorders within the past 6 weeks or vasculitis with diffused alveolar hemorrhage
  • Diagnosis of bleeding peptic ulcer disease within the previous 2 months
  • Congenital bleeding diatheses such as hemophilia
  • Treatment with anti-platelet, anti-coagulant agents, or non-steroidal anti-inflammatory drugs (NSAIDs)within 72 hours following infusion of study drug
  • Therapeutic heparin:
  • Unfractionated heparin within eight hours prior to study drug infusion
  • Low molecular weight heparins within the 12 hours prior to study drug infusion
  • Prophylactic heparin:
  • Unfractionated heparin \>15,000 units/day
  • Low molecular weight heparins
  • Warfarin if used within 7 days prior to study drug infusion
  • Thrombolytic treatment within 3 days prior to study drug infusion
  • 8Glycoprotein IIb/IIIa antagonists within 7 days prior to study drug infusion
  • Aspirin or any aspirin containing compound within 3 days prior to study drug infusion
  • APC infusion within 72 hours prior to study drug infusion
  • Major trauma or trauma subjects at an increased risk of bleeding
  • History of severe head trauma that required hospitalization, intracranial surgery, or stroke or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion with an epidural catheter or who anticipate receiving an epidural catheter during study drug infusion
  • Major surgery within the previous 3 days, any postoperative subject with evidence of active bleeding, or any subject with planned or anticipated surgery within 72 hours after study drug infusion. History of abnormal bleeding during surgical procedures
  • Chronic renal failure, defined as a calculated glomerular filtration rate (GFR) ≤20 mL/min
  • Subjects with baseline aspartate transaminase (AST) or alanine transaminase (ALT) level \>5 times the upper limit of normal. Subjects with known esophageal varices, chronic jaundice, biopsy proven cirrhosis, or chronic ascites
  • History of organ transplant (including bone marrow)
  • Subjects with malignancy having a life expectancy \<6 months
  • Known human immunodeficiency virus (HIV) positive with CD4+ T Cell count \<200/uL
  • Women who are pregnant or nursing
  • Participation in another clinical research study within 30 days before administration of study drug, with the exception of participation in studies involving noninvasive monitoring medical devices
  • Any prior treatment with a murine or chimeric antibody
  • Subjects who are moribund and where death is perceived to be imminent (within 72 hours after screening)
  • Subjects who have persistent hypotension not responding to fluid or vasopressor administration; subjects who require more than two vasopressors 26. Any medical condition which in the opinion of the investigator would interfere with optimal participation in the study or that would produce a significant risk to a subject

Key Trial Info

Start Date :

December 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2008

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT01438853

Start Date

December 1 2004

End Date

February 1 2008

Last Update

January 6 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

University of Miami

Miami, Florida, United States, 33125

2

Beth Israel Deconess Medical Center

Boston, Massachusetts, United States, 02215

3

Washington University

St Louis, Missouri, United States, 63130

4

Wake Forest University

Winston-Salem, North Carolina, United States, 27157